Navigation Links
Eigen Receives Two Grant Awards from U.S. Department of Health & Human Services
Date:4/22/2011

GRASS VALLEY, Calif., April 22, 2011 /PRNewswire/ -- Eigen is the proud recipient of two grant awards from the Qualifying Therapeutic Discovery Project (QTDP) funded by the U.S. Department of Health & Human Services. QTDP tax credits are provided under section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). Eigen received the maximum $244,000 award for each grant awarded in October, 2010, and January, 2011. These credits support biomedical research by small companies which may have major impact on the diagnosis and treatment of significant diseases.  

With this grant, Eigen continues to rapidly move forward, bringing breakthrough medical imaging products to market. Additionally, the QTDP grants have enabled the company to hire additional local talent to support growing company needs.  

Artemis, Eigen's flagship product, uses proprietary, next-generation imaging technology and provides solutions—not previously available—which enhance urologists' existing 2D ultrasound imagery with full color 3D modeling used for "smart" prostate biopsies.

"Artemis has provided a great leap forward in the diagnosis of prostate cancer," says Brian Burr, Eigen CEO. "It has added precision along with the ability to guide, track, and record exact biopsy locations. Artemis lets doctors re-biopsy the same location accurately in a subsequent biopsy. This has previously not been an option. Artemis technology provides high quality, real-time information that enhances how prostate cancer is managed. Better patient information equals better patient decisions."

Eigen is also breaking into the prostate cancer therapy market.  The company hopes to receive future support from such programs as the QTDP, allowing it to continue providing quality imaging devices to medical professionals worldwide.

About Eigen

Eigen is a world leader in the development of innovative imaging devices and technology that lets healthcare professionals improve their ability to visualize, diagnose and determine appropriate treatment pathways in over 4,000 hospitals worldwide. Located at 13366 Grass Valley Avenue, Grass Valley, CA  95945, visit Eigen at www.eigen.com.


'/>"/>
SOURCE Eigen
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents
2. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
3. Morphotek®, Inc. Receives Beacon Award From CancerCare
4. Cellectis Receives Payment for License to Homologous Recombination Patents
5. China-Biotics Receives First U.S. Sales Order
6. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
7. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
8. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
9. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
10. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
11. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... England , January 23, 2017 ... today announces completion of its Series D financing, raising $35 ... one new investor, Wondfo Biotech. ... Development of the Atlas Genetics io® ... the Chlamydia trachomatis (CT) test announced in February 2016.  This ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L ... the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices ... and scientific consultants and contractors. This is the latest step in G&L’s expansion ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):